Q32 Bio Inc. (QTTB) Stock Price & Analysis
Q32 Bio Inc. (QTTB) fell 1.50% to USD 15.15 as of July 25, 2026 at 04:14 UTC, according to Nexqual real-time market data.
QTTB last closed at USD 15.38; the session ranged USD 14.97–15.59 on volume of 178,785 shares. Market capitalization is $450.09M, with a 52-week range of USD 1.57–23.57 (NCM). Source: Nexqual, July 25, 2026 at 04:14 UTC.
Key Statistics (as of July 25, 2026 at 04:14 UTC)
| Price | USD 15.15 |
|---|---|
| Change | ▼ 1.50% (down) |
| Previous Close | USD 15.38 |
| Open | USD 15.46 |
| Day Range | USD 14.97 – 15.59 |
| 52-Week Range | USD 1.57 – 23.57 |
| Volume | 178,785 shares |
| Market Cap | $450.09M |
| Exchange | NCM |
Technical Analysis (QTTB)
Nexqual's technical model rates QTTB "STRONG BUY" based on 5 bullish and 0 bearish signals across 125 daily candles, as of July 25, 2026 at 04:14 UTC.
| Overall Signal | STRONG BUY |
|---|---|
| RSI (14) | 52.25 (neutral) |
| vs SMA50 | Above (USD 12.09) |
| MACD | 0.98 (positive) |
Analyst Ratings (QTTB)
Wall Street analysts rate QTTB "Strong Buy" based on 4 analysts, with a mean price target of USD 38.75 (range USD 13–66), per Nexqual as of July 25, 2026 at 04:14 UTC.
| Consensus Rating | Strong Buy |
|---|---|
| Analyst Count | 4 |
| Mean Target | USD 38.75 |
| High Target | USD 66 |
| Low Target | USD 13 |
| Buy / Hold / Sell | 5 / 0 / 0 |
Earnings (QTTB)
| Revenue Estimate | $600,000 |
|---|
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -0.54 vs est -0.68 ▲ beat |
| 2025-12-31 | USD 4.58 vs est -0.86 ▲ beat |
| 2025-09-30 | USD -0.6 vs est -1.19 ▲ beat |
| 2025-06-30 | USD -0.78 vs est -0.98 ▲ beat |
Source: Nexqual, July 25, 2026 at 04:14 UTC.
Financials & Fundamentals (QTTB)
| Total Revenue | $53.74M |
|---|---|
| Gross Margin | +71.62% |
| Operating Margin | +39.84% |
| Profit Margin | +61.86% |
| ROE | +157.18% |
| Debt / Equity | 29.47 |
| Current Ratio | 5.36 |
| Total Cash | $50.75M |
| Total Debt | $13.65M |
| Free Cash Flow | $9.87M |
Source: Nexqual, July 25, 2026 at 04:14 UTC.
Financial Health Score (QTTB)
Nexqual rates Q32 Bio Inc.'s overall financial health "Strong" across five dimensions, as of July 25, 2026 at 04:14 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Strong — Gross margin 72%, operating 40% |
| Balance Sheet | Strong — $51M cash vs $14M debt, net cash position |
| Cash Flow | Strong — FCF $10M, 18% margin |
| Efficiency | Strong — ROE 157%, ROA 18.7% |
Ownership (QTTB)
| Insider Ownership | +4.56% |
|---|---|
| Institutional Ownership | +107.23% |
| Shares Outstanding | 29.71M |
| Float | 2.60M |
| Short % of Float | +8.31% |
Source: Nexqual, July 25, 2026 at 04:14 UTC.
Leadership (QTTB)
Q32 Bio Inc. is led by Jodie Pope Morrison (age 49), CEO & Director, per Nexqual as of July 25, 2026 at 04:14 UTC.
| CEO & Director | Jodie Pope Morrison (age 49) |
|---|---|
| CFO & President | Lee H. Kalowski (age 44) |
| Co-founder, Chief Scientific Officer & President of Research | Shelia M. Violette (age 64) |
Major Backers & Investors (QTTB)
Notable institutional backers of Q32 Bio Inc. include Orbimed Advisors LLC., Atlas Venture Life Science Advisors, LLC , Opaleye Management Inc., according to Nexqual as of July 25, 2026 at 04:14 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Orbimed Advisors LLC. | 7.57% |
| Atlas Venture Life Science Advisors, LLC | 7.03% |
| Opaleye Management Inc. | 4.22% |
| Carlyle Group Inc. | 3.7% |
| Arch Venture Management, Llc | 1.08% |
| Acorn Capital Advisors, LLC | 1.06% |
| American Century ETF Trust-Avantis U.S. Small Cap Value ETF | 0.84% |
| Mackenzie Financial Corporation | 0.83% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 2.06% |
Source: Nexqual, July 25, 2026 at 04:14 UTC.
From Q32 Bio Inc.'s Latest SEC 10-K Filing (filed 2026-03-10)
Key Strengths & Strategy (as disclosed to the SEC)
- Q32 Bio Inc., a clinical-stage biotechnology company, develops novel biologics to restore healthy immune balance in patients with alopecia areata and other autoimmune and inflammatory diseases driven by pathological immune dysfunction.
- The company is developing Bempikibart (ADX-914), a fully human antiinterleukin-7 receptor alpha antagonist monoclonal antibody which completed Phase 2a clinical trials, designed to re-regulate adaptive immune function by blocking signaling mediated by interleukin-7 and thymic stromal lymphopoietin for the treatment of atopic dermatitis and alopecia areata.
- It also develops ADX-096, a C3d mAb CR1 fusion protein for use in ophthalmologic indications, as well as other C3d mAb fusions and nanobodies designed for tissue-targeted complement inhibition and a range of other indications.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| PLRZ | Polyrizon Ltd. | USD 14.68 | ▲ 2.02% |
| ARTV | Artiva Biotherapeutics, Inc. | USD 10.03 | ▲ 0.1% |
| CRVO | CervoMed Inc. | USD 2.66 | ▼ 4.32% |
| SDOT | Sadot Group Inc. | USD 17.52 | ▼ 13.61% |
| AHMA | Ambitions Enterprise Management | USD 1.59 | ▼ 5.92% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 04:14 UTC. This page is informational and not investment advice.